CG Oncology, Inc. (CGON) stock
CGONNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$78.94−5.84 (-6.89%)
Close on Nov 17, 2026Market cap $7.00BP/E –Yield –
CG Oncology r&d expenses
Research and development expenses are spending on new products and technology.
CG Oncology's R&D Expenses for the twelve months ending Sep 30, 2026 was $167.57M, up 47.7% year over year. For fiscal 2025 it was $116.64M, up 42.1% from the year before.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $116.64M | +42.1% |
| FY2024 | Dec 31, 2024 | $82.10M | +79.5% |
| FY2023 | Dec 31, 2023 | $45.75M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $39.22M | +40.7% |
| Q2 FY2026 | Jun 30, 2026 | $54.66M | +74.5% |
| Q1 FY2026 | Mar 31, 2026 | $43.73M | +59.2% |
| Q4 FY2025 | Dec 31, 2025 | $29.96M | +11.8% |
| Q3 FY2025 | Sep 30, 2025 | $27.88M | +42.1% |
| Q2 FY2025 | Jun 30, 2025 | $31.33M | +69.6% |
| Q1 FY2025 | Mar 31, 2025 | $27.47M | +59.6% |
| Q4 FY2024 | Dec 31, 2024 | $26.80M | +64.0% |
| Q3 FY2024 | Sep 30, 2024 | $19.62M | +67.2% |
| Q2 FY2024 | Jun 30, 2024 | $18.47M | +87.9% |
| Q1 FY2024 | Mar 31, 2024 | $17.21M | +119.5% |
| Q4 FY2023 | Dec 31, 2023 | $16.34M | – |
| Q3 FY2023 | Sep 30, 2023 | $11.74M | – |
| Q2 FY2023 | Jun 30, 2023 | $9.83M | – |
| Q1 FY2023 | Mar 31, 2023 | $7.84M | – |
See a number that looks wrong?